<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00991055</url>
  </required_header>
  <id_info>
    <org_study_id>HR-96-61</org_study_id>
    <nct_id>NCT00991055</nct_id>
  </id_info>
  <brief_title>Comparison of the Efficacy and Safety Between Pioglitazone and Placebo Added to Combination Therapy in Type 2 Diabetes</brief_title>
  <official_title>To Compare the Efficacy and Safety Between Pioglitazone Added to Combination Therapy of Sulfonylurea Plus Metformin and Placebo Control Group in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cheng-Kung University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cheng-Kung University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to study the efficacy and safety of pioglitazone added to&#xD;
      combination therapy of sulfonylurea plus metformin with placebo in patients with type 2&#xD;
      diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pioglitazone hydrochloride, a thiazolidinedione compound, is a new therapeutic agent for the&#xD;
      treatment of type 2 diabetes that reduces insulin resistance by enhancing insulin action in&#xD;
      skeletal muscle, liver, and adipose tissue. In the study of diabetes, pioglitazone reduced&#xD;
      the hyperglycemia, hyperinsulinemia, and hypertriglyceridemia characteristic of&#xD;
      insulin-resistant states. The metabolic changes induced by pioglitazone result in increased&#xD;
      responsiveness of insulin-dependent tissues and are observed in numerous models of insulin&#xD;
      resistance.&#xD;
&#xD;
      In the present randomized, double-blind, parallel study, we aim to compare the efficacy and&#xD;
      safety of pioglitazone added to combination therapy of sulfonylurea plus metformin with those&#xD;
      of sulfonylurea plus metformin for the treatment of type 2 diabetic patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2008</start_date>
  <completion_date type="Anticipated">October 2010</completion_date>
  <primary_completion_date type="Anticipated">June 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change from baseline in HbA1Cand FPG</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin resistance (HOMA-IR index)</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Pioglitazone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>A total 16-week randomized, double-blind, controlled study to compare the efficacy and safety of pioglitazone 15mg once daily added to combination metformin plus sulfonylurea with those of placebo combining control group.&#xD;
(4-week run in period and 12-week pioglitazone 15mg added to combination therapy of sulfonylurea plus metformin and placebo control group in patients with type 2 diabetes)</description>
    <arm_group_label>Pioglitazone</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or Female, Aged &gt; 25 years and had been diagnosed as type 2 diabetes for at least&#xD;
             3 months before study entry.&#xD;
&#xD;
          2. Subjects have taken sulfonylurea plus metformin therapy for at least 3 months before&#xD;
             study entry.&#xD;
&#xD;
          3. Subjects have to take daily Metformin 500~2000mg tolerable dosages and sulfonylurea&#xD;
             (such as the usage dose of glimepiride ≧4mg; dose of Gliclazide≧160mg; dose of&#xD;
             Glipizide ≧20mg; dose of glyburide≧4mg) for at least 1 months.&#xD;
&#xD;
          4. Those subjects with HbA1C historical levels between 7.0% and 11.0% within 3 month&#xD;
             prior to study entry.&#xD;
&#xD;
          5. BMI between 20-35 kg /m2.&#xD;
&#xD;
          6. Each subject must have a level of understanding sufficient to agree to all tests and&#xD;
             examinations required by the protocol and must sign an informed consent document.&#xD;
&#xD;
          7. Subjects have been under stable diet control for at least 1 month before study entry.&#xD;
&#xD;
          8. Subjects are willing to stick to current diet and sulfonylurea plus metformin&#xD;
             treatment plan during this trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant women or lactating mothers.&#xD;
&#xD;
          2. Type 1 DM(IDDM), or diabetes caused by pancreas damage、secondary forms of diabetes,&#xD;
             i.e., Cushing's syndrome or acromegaly.&#xD;
&#xD;
          3. A history of acute metabolic complication within 3 months before study entry, i.e.,&#xD;
             ketoacidosis or hyperosmolar state (coma).&#xD;
&#xD;
          4. There are significant macrovascular complications (i.e. unstable angina or acute&#xD;
             myocardial infarction) or renal impairment (serum creatinine higher than 1.5 mg/dL).&#xD;
&#xD;
          5. Have a known allergy to pioglitazone.&#xD;
&#xD;
          6. Other medications can be taken if their use had been instituted before study entry,&#xD;
             but agents that can interfere with study evaluations, including other oral&#xD;
             antidiabetic agents and corticosteroids, were not allowed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ta-Jen Wu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cheng Kung University College and Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ta-Jen Wu, Dr</last_name>
      <phone>886-6-2353535</phone>
      <phone_ext>5387</phone_ext>
      <email>djwu@mail.ncku.edu.tw</email>
    </contact>
    <investigator>
      <last_name>Ta-Jen Wu, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <study_first_submitted>October 1, 2009</study_first_submitted>
  <study_first_submitted_qc>October 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2009</study_first_posted>
  <last_update_submitted>October 6, 2009</last_update_submitted>
  <last_update_submitted_qc>October 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2009</last_update_posted>
  <responsible_party>
    <name_title>National Cheng-Kung University Hospital</name_title>
    <organization>National Cheng-Kung University Hospital</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

